Latest Asx News

The Supreme Court of Western Australia has approved the share and option schemes for Capricorn Metals’ acquisition of Warriedar Resources, setting the stage for a significant consolidation in the gold exploration sector.

Novatti Group has attracted a $1 million investment from Australian Wealth Advisors Group to fuel its renewed growth strategy, focusing on expanding its Acquiring business following positive early financial results.

Tombador Iron Limited has completed its strategic acquisition of GoviEx Uranium Inc., paving the way for a relisting as Atomic Eagle Ltd focused on uranium exploration.

Sequoia Financial Group’s subsidiary InterPrac Financial Planning faces ASIC civil penalty proceedings over past investment advice but plans a robust defence.

Island Pharmaceuticals will host a webinar to discuss the FDA's feedback on the clinical development and regulatory approval of its antiviral drug Galidesivir, including key considerations under the FDA's Animal Rule and Priority Review Voucher eligibility.

Volt Group Limited is set to acquire Perth-based 4D Delta Pty Ltd for $7.25 million, adding a profitable digital asset inspection business to its portfolio. The acquisition is supported by a $4 million capital raise and aims to accelerate Volt’s growth in technology-enabled resource services.

DroneShield Limited has clarified the recent sharp decline in its share price, attributing the market movement to disclosed director share disposals rather than any undisclosed material information.

Resolution Minerals has clarified its compliance with ASX disclosure rules following a $2 million placement to Tribeca Investment Partners, confirming the transaction's material impact on its share price.

Cauldron Energy’s 2025 drilling campaign at Manyingee South has intersected significant high-grade uranium mineralisation, expanding the deposit’s footprint and reinforcing the Yanrey Project’s potential amid rising global uranium demand.

EBOS Group Limited has updated its Dividend Reinvestment Plan rules, offering shareholders new ways to reinvest dividends into additional shares. The changes, effective immediately, provide greater flexibility and maintain board discretion over share issuance terms.

Chimeric Therapeutics reports promising interim results from its CHM CDH17 Phase 1/2 trial, with 75% disease control at 28 days and durable responses in gastrointestinal cancers.

Rokeby Resources has identified a suite of new high-grade gold and antimony prospects at its Hurricane Project in northern Queensland, confirming a district-scale mineralised system. The findings set the stage for an upcoming drilling campaign aimed at unlocking the project's full potential.